The DOCK7 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population in which the human DOCK7 gene has been disrupted to create a loss-of-function model for functional studies. This product provides a heterogeneous pool of edited cells, each carrying a distinct genetic alteration at the DOCK7 locus, enabling the investigation of gene function without the assumption of clonal homogeneity. By eliminating DOCK7 expression, researchers can dissect its role in guanine nucleotide exchange factor (GEF) activity toward Rac1 and Cdc42, deciphering mechanisms that underlie actin cytoskeleton dynamics and cell migration. The polyclonal nature offers a robust, scalable source of knockout cells, suitable for a wide range of biochemical, imaging, and genetic screening applications in haploid cellular contexts.
The host cell line, HAP1, is a near-haploid human chronic myeloid leukemia-derived line with an adherent fibroblast-like morphology. Originating from the KBM-7 cell line, HAP1 cells have become a widely adopted model for functional genomics and CRISPR-based screens due to their haploid chromosomal content, which simplifies genotype-phenotype correlations and eliminates confounding effects from a second allele. This genetic simplicity accelerates the generation of knockout populations and facilitates high-content readouts, including cell migration, viability, and morphological assays. The HAP1 background is particularly well-suited for studying genes involved in cell signaling and migration, as it provides a consistent and manipulable platform free from the complexities of diploid compensation.
DOCK7 encodes a member of the DOCK family of atypical GEFs that specifically activates Rac1 and Cdc42 by catalyzing GDP-to-GTP exchange, leading to downstream actin polymerization and cytoskeletal reorganization. Functioning as part of a multiprotein signaling complex, DOCK7 interacts with the adaptor protein ELMO1, and is regulated by integrin signaling, receptor tyrosine kinases, and Ras activation. Once activated, it promotes the formation of GTP-bound Rac1 and Cdc42, which subsequently trigger a cascade involving PAK1, LIMK1, and cofilin to modulate actin filament dynamics. This pathway is essential for a variety of cellular processes including neuronal migration, axon guidance, and immune cell chemotaxis. Mutations in DOCK7 are linked to epileptic encephalopathy, intellectual disability, and other neurodevelopmental disorders, while aberrant DOCK7 activity has been implicated in cancer metastasis through enhanced cell motility.
In the HAP1 haploid background, DOCK7 knockout polyclonal cells offer a powerful system to interrogate Rac1/Cdc42-dependent signaling without the compensatory effects of a second intact allele. This model enables precise assessment of cell migration defects using scratch/wound-healing assays, visualization of actin cytoskeleton changes via phalloidin staining, and quantification of GTPase activation states through pull-down experiments. The haploid nature also enhances the signal-to-noise ratio in genetic screens aimed at identifying synthetic lethal interactions, drug sensitizers, or novel pathway modulators linked to DOCK7. Additionally, these cells can be used to model neurodevelopmental phenotypes by assessing neurite outgrowth or growth cone dynamics when differentiated or stimulated with relevant cues.
The DOCK7 Knockout HAP1 Polyclonal Cells are optimally suited for a broad array of research applications, including detailed dissection of Rac1/Cdc42-mediated cytoskeletal dynamics, high-content migration screens, and pathway mapping using RNA sequencing or proteomics. Researchers probing neurodevelopmental disease mechanisms can utilize these cells to study neuronal morphogenesis, while cancer biologists may explore the role of DOCK7 in metastatic dissemination. Representative assays include western blotting for DOCK7, GTPase activation assays using Rac1/Cdc42 pull-down probes, immunofluorescence for neuronal markers, and transcriptome profiling. For further information, please contact Ascent Research.
